Examination of Tamoxifen in Acute Mania in Patients With Bipolar I Disorder
A Double-Blind Study Examining the Efficacy of the Protein Kinase C Inhibitor Tamoxifen in the Treatment of Acute Mania
2 other identifiers
interventional
50
1 country
1
Brief Summary
The purpose of this study is to examine how the drug tamoxifen affects the brain in patients with bipolar I disorder. Bipolar Disorder (BD) is a severe, chronic, and often life-threatening illness for which safe and effective treatments are necessary. The mood stabilizing effects of lithium and valproate have revolutionized the treatment of patients with BD. However, a significant percentage of patients do not respond fully to these drugs, and the biochemical basis for the antimanic and mood-stabilizing actions of lithium and valproate is unclear. Both drugs inhibit protein kinase C (PKC). There is a need to investigate the efficacy of a direct PKC inhibitor in the treatment of acute mania. Tamoxifen is currently the only relatively selective PKC inhibitor available for human use. Participants in this study will be screened with a physical, psychiatric, and eye examination and blood and urine tests. Eligible participants will be hospitalized at the Clinical Center for at least 4 weeks. They will be tapered off all psychiatric medication and kept drug free for 2 to 7 days. They will also be put on a low-monoamine, low-caffeine diet. Participants will be randomly assigned to receive either tamoxifen or placebo (an inactive pill) for 3 weeks. During this time, participants will have daily pulse and blood pressure measurements, several electrocardiograms (EKGs), and blood draws. Weight measurements will be taken at least twice during the study, and caffeine or dextromethorphan will be given at the beginning and end of the study to test how tamoxifen affects the way the body eliminates other medications. Participants will have a physical examination at the end of the study. At the end of this 4-week study, some participants may continue the study and will receive tamoxifen for an additional 3 weeks. At the conclusion of the study, participants' psychiatric status will be reassessed and long-term psychiatric treatment for their mood disorders will be arranged.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
Started Nov 2001
Longer than P75 for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 9, 2001
CompletedFirst Submitted
Initial submission to the registry
November 10, 2001
CompletedFirst Posted
Study publicly available on registry
November 12, 2001
CompletedStudy Completion
Last participant's last visit for all outcomes
November 2, 2007
CompletedJuly 2, 2017
May 20, 2008
November 10, 2001
June 30, 2017
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Patients may be included in the study only if they meet all of the following criteria:
- Male and female patients, 18 to 65 years of age. \[Note: Only females who are premenopausal with regular menstrual cycles will be able to participate\].
- Female subjects of childbearing potential must be using a medically accepted means of contraception.
- Each patient must have a level of understanding sufficient to agree to all tests and examinations required by the protocol.
- Each patient must understand the nature of the study and must sign an informed consent document. We will not permit patients with a Durable Power of Attorney (DPA) to participate in this study. We will however, encourage all patients to sign a DPA after signing the informed consent. However, signing a DPA is not a requirement for participating in this study.
- Patients must have a diagnosis of bipolar I disorder and currently display an acute manic or mixed episode (with or without psychotic features) according to the DSM-IV based on clinical assessment and confirmed by structured diagnostic interview SCID-P. This includes the following diagnoses: 296.4x, Bipolar I Disorder, Most Recent Episode Manic; 296.6x, Bipolar I Disorder, Most Recent Episode Mixed.
- Patients must have a YMRS total score of greater than or equal to 14 at both Visits 1 and 2.
- No decrease in total score of YMRS of greater than or equal to 20% during washout (between Visits 1 and 2).
- DSM-IV rapid cyclers will be permitted to participate in this study.
- Duration of current manic episode of not more than 4 weeks.
- Previous trial with any one of the following antimanic agents: lithium, valproate, carbamazepine, oxcarbazepine, typical antipsychotic drug, or atypical antipsychotic drug (olanzapine, risperidone, ziprasidone, aripiprazole, quetiapine). If the subject has not previously taken one of these antimanic treatments, then the research physician may start one of them at NIH. Subjects not responding to a 3 week trial of an antimanic agent of their choice (at least a 50% decrease on the YMRS rating scale from baseline) will be eligible to be randomized if they continue to meet study criteria.
You may not qualify if:
- Patients will be excluded from the study for any of the following reasons:
- Female patients who are either pregnant, nursing, or who are perimenopausal or postmenopausal.
- QTc of greater than 450 msec.
- Participation in a clinical trial of another investigational drug within 1 month (30 days) prior to study entry (Visit 1).
- Has received an antidepressant within 4 weeks prior to Visit 1 \[8 weeks for fluoxetine\].
- Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.
- Presence of a coagulation disorder, history of deep venous thrombosis or pulmonary embolism.
- History of breast or uterine cancer, or abnormal uterine bleeding.
- Uncorrected hypothyroidism or hyperthyroidism.
- Presence of retinal pathology.
- One or more seizures without a clear and resolved etiology.
- Current leukopenia or thrombocytopenia.
- Clinical significant abnormal laboratory tests.
- Documented history of hypersensitivity or intolerance to TAM.
- DSM-IV substance abuse or dependence (except nicotine and caffeine) within the past 30 days.
- +8 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Howard University Hospital
Washington D.C., District of Columbia, 20060, United States
Related Publications (1)
Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol. 1999 Apr;19(2):155-63. doi: 10.1097/00004714-199904000-00011.
PMID: 10211917BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Purpose
- TREATMENT
- Sponsor Type
- NIH
Study Record Dates
First Submitted
November 10, 2001
First Posted
November 12, 2001
Study Start
November 9, 2001
Study Completion
November 2, 2007
Last Updated
July 2, 2017
Record last verified: 2008-05-20